. Author manuscript; available in PMC: 2021 Apr 6.

Published in final edited form as: Nat Rev Clin Oncol. 2019 Dec 13;17(4):233–250. doi: 10.1038/s41571-019-0299-9

Table 2 |.

pCR rates in trials of neoadjuvant dual HER2-targeted therapy plus chemotherapy

Clinical trial	Dual HER2 therapy	pCR with single-agent HER2-targeted therapy agent (%)	pCR with dual HER2 therapy (%)
NeoALTTO²⁶	L+T	T: 30 (95% CI 22.4–37.5) L: 25 (95% CI 18.1–32.3)	51 (95% CI 43.1–59.5; P=0.0001)
NeoSphere⁴⁷	T+P	T: 29 (95% CI 20.6–38.5) P: 24 (95% CI 15.8–33.7)	46 (95% CI 36.1–55.7; P=0.0141)
CALGB 40601 (REF.⁹¹)	L+T	T: 40 (95% CI 32–49) L: 32 (95% CI 22–44)	51 (95% CI 42–60; P=0.11)
NSABP B-41 (REF.⁹⁴)	L+T	T: 53 (95% CI 44.9–59.5) L: 53 (95% CI 45.4–60.3)	62 (95% CI 54.3–68.8; P=0.095)
Tryphaena⁹⁵	T+P	NA	57–66^a

CI, confidence interval; L, lapatinib; NA, not applicable; P, pertuzumab; pCR, pathological complete response; T, trastuzumab.

95% CI presented graphically in REF.⁹⁵.